Two-Dimensional Electrophoresis in Prostate Cancer Research and Diagnostics

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Labmedicine

• Publication date

  2007-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1309/9TMWPME1Q1MK3N39
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Immobilized pH gradients

  2009cited by this paper
• Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.

  2007cited by this paper
• Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples.

  2007cited by this paper
• Alterations in the serum glycome due to metastatic prostate cancer.

  2007cited by this paper
• Proteomics in prostate cancer research.

  2007cited by this paper
• Proteomics for the identification of new prostate cancer biomarkers.

  2006cited by this paper
• Different glycan structures in prostate-specific antigen from prostate cancer sera in relation to seminal plasma PSA.

  2006cited by this paper
• Mass Spectrometric Identification of Human Prostate Cancer-derived Proteins in Serum of Xenograft-bearing Mice*

  2006cited by this paper
• Proteomics in prostate cancer

  2005cited by this paper
• Limitations of current proteomics technologies.

  2005cited by this paper
• Revealing urologic diseases by proteomic techniques.

  2005cited by this paper
• Comparison by LC-MS and MALDI-MS of prostate-specific antigen from five commercial sources with certified reference material 613.

  2005cited by this paper
• On the Role of Cell Surface Carbohydrates and their Binding Proteins (lectins) in Tumor Metastasis

  2004cited by this paper
• Proteomic patterns for early cancer detection.

  2004cited by this paper
• Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer.

  2004cited by this paper
• Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.

  2004cited by this paper
• Nano-scale proteomics approach using two-dimensional fibrin zymography combined with fluorescent SYPRO ruby dye.

  2004cited by this paper
• Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml.

  2003cited by this paper
• Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins.

  2003cited by this paper
• Detection technologies in proteome analysis.

  2002cited by this paper
• Proteomic analysis of human prostate cancer †

  2002cited by this paper
• Differential diagnosis of prostate cancer and benign prostate hyperplasia using two‐dimensional electrophoresis

  2001cited by this paper
• Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry.

  2001cited by this paper
• Prostate specific antigen: biology, biochemistry and available commercial assays

  2001cited by this paper
• A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer.

  2001cited by this paper
• Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.

  2000cited by this paper
• The current state of two‐dimensional electrophoresis with immobilized pH gradients

  2000cited by this paper
• Proteomics: Capacity versus utility

  2000cited by this paper
• "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia.

  2000cited by this paper
• A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue.

  2000cited by this paper
• Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.

  2000cited by this paper
• Prostate specific antigen: a decade of discovery--what we have learned and where we are going.

  1999cited by this paper
• Efficiency of prostate‐specific antigen and digital rectal examination in screening, using 4.0 ng/ml and age‐specific reference range as a cutoff for abnormal values

  1999cited by this paper
• Molecular Heterogeneity of Free PSA in Sera of Patients with Benign and Malignant Prostate Tumors

  1999cited by this paper
• Purification of prostate-specific antigen from human serum by indirect immunosorption and elution with a hapten.

  1999cited by this paper
• 2D protein electrophoresis: can it be perfected?

  1999cited by this paper
• Glycoprotein glycosylation and cancer progression.

  1999cited by this paper
• Two‐dimensional electrophoresis of prostate‐specific antigen in sera of men with prostate cancer or benign prostate hyperplasia

  1999cited by this paper
• Analyzing glycoproteins separated by two‐dimensional gel electrophoresis

  1998cited by this paper
• Prostate-specific Antigen: Its Usefulness in Clinical Medicine.

  1998cited by this paper
• Role of PSA and its indices in determining the need for repeat prostate biopsies.

  1997cited by this paper
• Prostate-specific antigen, clinical use and staging: an overview.

  1997cited by this paper
• Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges.

  1997cited by this paper
• Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate.

  1991cited by this paper
• Isoelectric focusing in immobilized pH gradients: principle, methodology and some applications.

  1982cited by this paper

• No citing papers are available for this paper.